Symbols / AVTX $15.91 -0.69%
AVTX Chart
About
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 294.54M |
| Enterprise Value | 179.44M | Income | -99.70M | Sales | 192.00K |
| Book/sh | 5.13 | Cash/sh | 6.16 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -3.50 | PEG | — |
| P/S | 1534.05 | P/B | 3.10 | P/C | — |
| EV/EBITDA | -2.71 | EV/Sales | 934.61 | Quick Ratio | 14.00 |
| Current Ratio | 14.28 | Debt/Eq | 0.61 | LT Debt/Eq | — |
| EPS (ttm) | -13.42 | EPS next Y | -4.55 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 07:00 | ROA | -37.18% |
| ROE | -174.79% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -346.32% | Profit Margin | 0.00% | Shs Outstand | 18.51M |
| Shs Float | 10.84M | Short Float | 19.98% | Short Ratio | 7.79 |
| Short Interest | — | 52W High | 20.72 | 52W Low | 3.39 |
| Beta | 0.89 | Avg Volume | 445.18K | Volume | 547.49K |
| Target Price | $36.11 | Recom | Strong_buy | Prev Close | $16.02 |
| Price | $15.91 | Change | -0.69% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$36.11
Mean price target
2. Current target
$15.38
Latest analyst target
3. DCF / Fair value
$-81.84
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$15.38
Low
$24.00
High
$50.00
Mean
$36.11
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | init | Guggenheim | — → Buy | $50 |
| 2026-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-12-18 | init | Mizuho | — → Outperform | $39 |
| 2025-09-29 | reit | BTIG | Buy → Buy | $40 |
| 2025-09-17 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-08-15 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-03-25 | init | Jefferies | — → Buy | $23 |
| 2025-03-25 | init | Stifel | — → Buy | $36 |
| 2025-03-20 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-02-28 | init | Piper Sandler | — → Overweight | $48 |
| 2024-12-19 | init | BTIG | — → Buy | $40 |
| 2024-12-17 | init | LUCID CAPITAL MARKETS | — → Buy | $24 |
| 2024-10-24 | init | HC Wainwright & Co. | — → Neutral | — |
| 2024-04-16 | up | Oppenheimer | Perform → Outperform | $35 |
- Avalo Therapeutics, Inc. $AVTX Shares Acquired by Boothbay Fund Management LLC - MarketBeat ue, 17 Mar 2026 08
- [144] Avalo Therapeutics, Inc. SEC Filing - Stock Titan Mon, 16 Mar 2026 20
- Avtx Wholesale Catalog AVTX Wholesale In Dallas, TX 75229 - 972-243 Wholesale Harry Hines - bussmagasinet.no Sat, 14 Mar 2026 20
- $AVTX stock is down 13% today. Here's what we see in our data. - Quiver Quantitative Mon, 01 Dec 2025 08
- Avalo Therapeutics, Inc.'s (NASDAQ:AVTX) institutional investors lost 11% over the past week but have profited from longer-term gains - simplywall.st ue, 16 Sep 2025 07
- Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX) - Yahoo Finance Wed, 29 Oct 2025 07
- Would You Still Hold Avalo Therapeutics Stock If It Fell 30%? - Trefis ue, 23 Dec 2025 08
- Boxer Capital Management LLC Invests $1.59 Million in Avalo Therapeutics, Inc. $AVTX - MarketBeat Sun, 15 Mar 2026 11
- Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug - Stocktwits Wed, 22 Oct 2025 08
- Biotech Avalo, focused on IL‑1β drugs, sets March investor chats - Stock Titan ue, 24 Feb 2026 08
- Avalo Therapeutics stock rises after Guggenheim initiates with Buy rating - Investing.com Mon, 02 Feb 2026 08
- We Think Avalo Therapeutics (NASDAQ:AVTX) Can Afford To Drive Business Growth - Yahoo Finance ue, 28 Oct 2025 07
- Avalo Therapeutics (AVTX) Expected to Announce Quarterly Earnings on Thursday - MarketBeat hu, 12 Mar 2026 05
- Will Avalo Therapeutics (NASDAQ:AVTX) Spend Its Cash Wisely? - simplywall.st Sat, 08 Nov 2025 08
- FMR LLC holds 2.13M shares of Avalo Therapeutics (NASDAQ: AVTX) — 11.5% - Stock Titan Fri, 06 Mar 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 8200 | 81016.0 | — | Conversion of Exercise of derivative security at price 9.88 per share. | GOLDMAN JONATHAN | Director | — | 2025-11-14 00:00:00 | D |
| 1 | 11367 | 162937.0 | — | Sale at price 14.30 - 14.35 per share. | GOLDMAN JONATHAN | Director | — | 2025-11-14 00:00:00 | D |
| 2 | 3167 | nan | — | — | KAPLAN GILLA | Director | — | 2025-03-28 00:00:00 | D |
| 3 | 3167 | nan | — | — | ALMENOFF JUNE SHERIE | Director | — | 2025-03-28 00:00:00 | D |
| 4 | 3167 | nan | — | — | GOLDMAN JONATHAN | Director | — | 2025-03-28 00:00:00 | D |
| 5 | 64867 | nan | — | — | NEIL GARRY A. M.D. | Chief Executive Officer | — | 2025-03-28 00:00:00 | D |
| 6 | 3167 | nan | — | — | CHAN MITCHELL | Director | — | 2025-03-28 00:00:00 | D |
| 7 | 24200 | nan | — | — | SULLIVAN CHRISTOPHER RYAN | Chief Financial Officer | — | 2025-03-28 00:00:00 | D |
| 8 | 3167 | nan | — | — | KANTOFF AARON | Director | — | 2025-03-28 00:00:00 | D |
| 9 | 3167 | nan | — | — | TRUEX SAMANTHA | Director | — | 2025-03-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 6.34M | -971.67K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.00 |
| NormalizedEBITDA | -98.53M | -18.66M | -37.27M | -80.48M |
| TotalUnusualItems | 30.18M | -4.63M | 0.00 | 0.00 |
| TotalUnusualItemsExcludingGoodwill | 30.18M | -4.63M | 0.00 | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | -35.13M | -31.54M | -41.66M | -84.35M |
| ReconciledDepreciation | 169.00K | 158.00K | 166.00K | 1.66M |
| ReconciledCostOfRevenue | -366.00K | 1.28M | 3.31M | 1.38M |
| EBITDA | -68.34M | -23.29M | -37.27M | -80.48M |
| EBIT | -68.51M | -23.44M | -37.44M | -82.13M |
| NetInterestIncome | 3.32M | -3.42M | -4.17M | -2.39M |
| InterestExpense | -3.32M | 3.42M | 4.17M | 2.39M |
| NormalizedIncome | -58.98M | -27.89M | -41.66M | -84.35M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -35.13M | -31.54M | -41.66M | -84.38M |
| TotalExpenses | 68.95M | 25.37M | 55.49M | 87.53M |
| TotalOperatingIncomeAsReported | -68.51M | -27.35M | ||
| DilutedAverageShares | 7.50M | 277.73K | 39.18K | 35.30K |
| BasicAverageShares | 4.43M | 277.73K | 39.18K | 35.30K |
| DilutedEPS | -20.91 | -113.58 | -1.06K | -2.39K |
| BasicEPS | -7.94 | -113.58 | -1.06K | -2.39K |
| DilutedNIAvailtoComStockholders | -35.13M | -31.54M | -41.66M | -84.38M |
| NetIncomeCommonStockholders | -35.13M | -31.54M | -41.66M | -84.38M |
| OtherunderPreferredStockDividend | -1.50M | |||
| NetIncome | -35.13M | -31.54M | -41.66M | -84.38M |
| NetIncomeIncludingNoncontrollingInterests | -35.13M | -31.54M | -41.66M | -84.38M |
| NetIncomeDiscontinuousOperations | 0.00 | -27.00K | ||
| NetIncomeContinuousOperations | -35.13M | -31.54M | -41.66M | -84.35M |
| TaxProvision | 114.00K | 14.00K | 28.00K | -196.00K |
| PretaxIncome | -35.02M | -31.53M | -41.63M | -84.55M |
| OtherIncomeExpense | 30.18M | -4.67M | -20.00K | -20.00K |
| OtherNonOperatingIncomeExpenses | -5.00K | -42.00K | -20.00K | -20.00K |
| SpecialIncomeCharges | -9.22M | -3.91M | 0.00 | 0.00 |
| OtherSpecialCharges | 9.22M | |||
| ImpairmentOfCapitalAssets | 0.00 | 3.91M | 0.00 | |
| RestructuringAndMergernAcquisition | 9.22M | 0.00 | ||
| GainOnSaleOfSecurity | 39.41M | -720.00K | ||
| NetNonOperatingInterestIncomeExpense | 3.32M | -3.42M | -4.17M | -2.39M |
| TotalOtherFinanceCost | -3.32M | 3.42M | 4.17M | 2.39M |
| InterestExpenseNonOperating | -3.32M | 3.42M | 4.17M | 2.39M |
| OperatingIncome | -68.51M | -23.44M | -37.44M | -82.13M |
| OperatingExpense | 69.32M | 24.08M | 52.06M | 86.04M |
| DepreciationAmortizationDepletionIncomeStatement | 0.00 | 38.00K | 1.55M | |
| DepreciationAndAmortizationInIncomeStatement | 0.00 | 38.00K | 1.55M | |
| Amortization | 0.00 | 38.00K | 1.55M | |
| AmortizationOfIntangiblesIncomeStatement | 0.00 | 38.00K | 1.55M | |
| ResearchAndDevelopment | 52.08M | 13.78M | 31.31M | 59.84M |
| SellingGeneralAndAdministration | 17.24M | 10.30M | 20.71M | 24.66M |
| SellingAndMarketingExpense | 789.00K | 33.00K | 76.00K | 1.66M |
| GeneralAndAdministrativeExpense | 16.45M | 10.27M | 20.64M | 23.00M |
| OtherGandA | 8.37M | 5.77M | 8.18M | 11.40M |
| SalariesAndWages | 8.08M | 4.50M | 12.46M | 11.60M |
| GrossProfit | 807.00K | 640.00K | 14.62M | 3.91M |
| CostOfRevenue | -366.00K | 1.28M | 3.43M | 1.49M |
| TotalRevenue | 441.00K | 1.92M | 18.05M | 5.40M |
| OperatingRevenue | 441.00K | 1.92M | 18.05M | 5.40M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 10.47M | 801.75K | 39.29K | 39.16K |
| ShareIssued | 10.47M | 801.75K | 39.29K | 39.16K |
| NetDebt | 6.24M | |||
| TotalDebt | 568.00K | 537.00K | 19.95M | 33.32M |
| TangibleBookValue | 122.53M | -3.20M | -25.32M | 8.63M |
| InvestedCapital | 133.03M | 7.30M | 8.50M | 55.91M |
| WorkingCapital | 131.93M | 3.78M | -5.70M | 41.96M |
| NetTangibleAssets | 122.53M | -3.20M | -25.32M | 8.63M |
| CapitalLeaseObligations | 568.00K | 537.00K | 532.00K | 485.00K |
| CommonStockEquity | 133.03M | 7.30M | -10.91M | 23.08M |
| TotalCapitalization | 133.03M | 7.30M | 2.57M | 55.91M |
| TotalEquityGrossMinorityInterest | 133.03M | 7.30M | -10.91M | 23.08M |
| StockholdersEquity | 133.03M | 7.30M | -10.91M | 23.08M |
| RetainedEarnings | -370.26M | -335.13M | -303.82M | -262.17M |
| AdditionalPaidInCapital | 503.29M | 342.44M | 292.91M | 285.24M |
| CapitalStock | 10.00K | 1.00K | 0.00 | 9.00K |
| CommonStock | 10.00K | 1.00K | 0.00 | 9.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 17.70M | 13.69M | 44.28M | 57.13M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.74M | 9.07M | 22.17M | 37.24M |
| OtherNonCurrentLiabilities | 2.35M | 3.37M | 3.71M | 4.30M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | ||
| DerivativeProductLiabilities | 8.12M | 5.55M | 4.83M | 0.00 |
| NonCurrentDeferredLiabilities | 270.00K | 155.00K | 141.00K | 113.00K |
| NonCurrentDeferredTaxesLiabilities | 270.00K | 155.00K | 141.00K | 113.00K |
| LongTermDebtAndCapitalLeaseObligation | 13.49M | 32.83M | ||
| LongTermDebt | 13.49M | 32.83M | ||
| CurrentLiabilities | 6.96M | 4.62M | 22.11M | 19.89M |
| OtherCurrentLiabilities | 360.00K | 480.00K | 9.00K | |
| CurrentDeferredLiabilities | 0.00 | 88.00K | 0.00 | |
| CurrentDeferredRevenue | 0.00 | 88.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 568.00K | 537.00K | 6.46M | 485.00K |
| CurrentCapitalLeaseObligation | 568.00K | 537.00K | 532.00K | 485.00K |
| CurrentDebt | 5.93M | |||
| OtherCurrentBorrowings | 5.93M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.88M | 580.00K | 2.70M | 4.31M |
| PayablesAndAccruedExpenses | 3.15M | 3.50M | 12.38M | 15.08M |
| CurrentAccruedExpenses | 2.54M | 3.06M | 8.99M | 11.34M |
| Payables | 610.00K | 446.00K | 3.39M | 3.74M |
| OtherPayable | 327.00K | 508.00K | 375.00K | |
| TotalTaxPayable | 0.00 | |||
| IncomeTaxPayable | 0.00 | |||
| AccountsPayable | 283.00K | 446.00K | 2.88M | 3.37M |
| TotalAssets | 150.73M | 20.99M | 33.37M | 80.21M |
| TotalNonCurrentAssets | 11.84M | 12.60M | 16.95M | 18.37M |
| OtherNonCurrentAssets | 131.00K | 131.00K | 131.00K | 1.23M |
| GoodwillAndOtherIntangibleAssets | 10.50M | 10.50M | 14.41M | 14.45M |
| OtherIntangibleAssets | 38.00K | |||
| Goodwill | 10.50M | 10.50M | 14.41M | 14.41M |
| NetPPE | 1.21M | 1.97M | 2.41M | 2.69M |
| AccumulatedDepreciation | -710.00K | -542.00K | -414.00K | -286.00K |
| GrossPPE | 1.92M | 2.51M | 2.83M | 2.98M |
| Leases | 1.64M | 2.23M | 739.00K | 739.00K |
| OtherProperties | 1.33M | 1.75M | 2.00M | |
| MachineryFurnitureEquipment | 282.00K | 282.00K | 336.00K | 241.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 138.89M | 8.39M | 16.42M | 61.84M |
| OtherCurrentAssets | 3.71M | 843.00K | 1.29M | 2.37M |
| RestrictedCash | 19.00K | 1.00K | 15.00K | 51.00K |
| PrepaidAssets | 2.37M | |||
| Inventory | 0.00 | 20.00K | 38.00K | |
| Receivables | 611.00K | 136.00K | 1.92M | 4.80M |
| OtherReceivables | 611.00K | 136.00K | 1.92M | 3.74M |
| AccountsReceivable | 0.00 | 1.06M | ||
| CashCashEquivalentsAndShortTermInvestments | 134.55M | 7.42M | 13.17M | 54.59M |
| CashAndCashEquivalents | 134.55M | 7.42M | 13.17M | 54.59M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -49.06M | -30.68M | -26.85M | -71.00M |
| RepurchaseOfCapitalStock | -14.81M | |||
| RepaymentOfDebt | 0.00 | -21.24M | 0.00 | 0.00 |
| IssuanceOfDebt | 0.00 | 32.90M | ||
| IssuanceOfCapitalStock | 115.62M | 46.22M | 34.00K | 71.93M |
| CapitalExpenditure | -95.00K | -113.00K | ||
| InterestPaidSupplementalData | 0.00 | 1.93M | 2.93M | 1.58M |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | ||
| EndCashPosition | 134.70M | 7.55M | 13.32M | 54.86M |
| BeginningCashPosition | 7.55M | 13.32M | 54.86M | 19.11M |
| ChangesInCash | 127.15M | -5.77M | -41.55M | 35.76M |
| FinancingCashFlow | 175.85M | 25.04M | -14.70M | 106.76M |
| CashFlowFromContinuingFinancingActivities | 175.85M | 25.04M | -14.70M | 106.76M |
| NetOtherFinancingCharges | -9.22M | |||
| ProceedsFromStockOptionExercised | 69.44M | 67.00K | 73.00K | 1.93M |
| NetCommonStockIssuance | 115.62M | 46.22M | -14.77M | 71.93M |
| CommonStockPayments | -14.81M | |||
| CommonStockIssuance | 115.62M | 46.22M | 34.00K | 71.93M |
| NetIssuancePaymentsOfDebt | 0.00 | -21.24M | 0.00 | 32.90M |
| NetLongTermDebtIssuance | 0.00 | -21.24M | 0.00 | 32.90M |
| LongTermDebtPayments | 0.00 | -21.24M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 32.90M | ||
| InvestingCashFlow | 356.00K | -133.00K | -95.00K | -113.00K |
| CashFlowFromContinuingInvestingActivities | 356.00K | -133.00K | -95.00K | -113.00K |
| NetOtherInvestingChanges | -158.00K | |||
| NetBusinessPurchaseAndSale | 356.00K | 0.00 | 0.00 | |
| SaleOfBusiness | 356.00K | 0.00 | 0.00 | |
| PurchaseOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | 0.00 | 25.00K | -95.00K | -113.00K |
| SaleOfPPE | 0.00 | 25.00K | 0.00 | |
| PurchaseOfPPE | 0.00 | -95.00K | -113.00K | |
| OperatingCashFlow | -49.06M | -30.68M | -26.75M | -70.89M |
| CashFlowFromContinuingOperatingActivities | -49.06M | -30.68M | -26.75M | -70.89M |
| ChangeInWorkingCapital | -4.71M | -9.24M | -60.00K | 2.84M |
| ChangeInOtherWorkingCapital | 70.00K | 88.00K | ||
| ChangeInOtherCurrentLiabilities | -88.00K | -76.00K | -9.00K | -45.00K |
| ChangeInOtherCurrentAssets | 0.00 | -1.00M | ||
| ChangeInPayablesAndAccruedExpense | -1.27M | -11.48M | -4.12M | 4.05M |
| ChangeInAccruedExpense | -1.11M | -9.05M | -3.63M | 3.25M |
| ChangeInPayable | -163.00K | -2.44M | -487.00K | 796.00K |
| ChangeInAccountPayable | -163.00K | -2.44M | -487.00K | 796.00K |
| ChangeInTaxPayable | 0.00 | 0.00 | ||
| ChangeInIncomeTaxPayable | 0.00 | 0.00 | ||
| ChangeInPrepaidAssets | -2.87M | 447.00K | 1.08M | 287.00K |
| ChangeInInventory | 0.00 | 20.00K | 18.00K | -35.00K |
| ChangeInReceivables | -475.00K | 1.78M | 2.88M | -414.00K |
| ChangesInAccountReceivables | 0.00 | 1.06M | 1.12M | |
| OtherNonCashItems | 24.05M | 1.83M | 1.39M | 794.00K |
| StockBasedCompensation | 5.85M | 3.48M | 7.55M | 8.17M |
| ProvisionandWriteOffofAssets | 1.00M | 0.00 | ||
| AssetImpairmentCharge | 0.00 | 3.91M | 0.00 | |
| DeferredTax | 114.00K | 14.00K | 28.00K | 22.00K |
| DeferredIncomeTax | 114.00K | 14.00K | 28.00K | 22.00K |
| DepreciationAmortizationDepletion | 169.00K | 158.00K | 166.00K | 1.66M |
| DepreciationAndAmortization | 169.00K | 158.00K | 166.00K | 1.66M |
| OperatingGainsLosses | -39.41M | 720.00K | 5.83M | |
| EarningsLossesFromEquityInvestments | 0.00 | |||
| GainLossOnInvestmentSecurities | -39.41M | 720.00K | 4.83M | |
| NetIncomeFromContinuingOperations | -35.13M | -31.54M | -41.66M | -84.38M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AVTX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|